Company Active LTD

Company profile

Disulfican Limited

Home | DISULFICAN LTD

Disulfican Limited is a UK company with status active founded in 2017 based in West Midlands.

CRN
10823844
Founded
2017
Age
9

Overview

Legal name
DISULFICAN LIMITED
Region
West Midlands
Registered address
UNIT 8
PENDEFORD BUSINESS PARK
WOLVERHAMPTON
ENGLAND
WV9 5HD
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

7 events
29 Jun
2026

Accounts due

Accounts Due

Next accounts due date

27 Jun
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

13 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

04 Oct
2024

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzQzODQyOTM0NmFkaXF6a2N4

Published 04 Oct 2024 12:13

04 Oct
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQzODQyODgwOWFkaXF6a2N4

Published 04 Oct 2024 12:07

30 Jun
2024

Accounts filed

Accounts

Last accounts made up date

16 Jun
2017

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2018
Funded years
2018, 2022
Age at first award
0 years

Projects

2022 Collaborative R&D Lead participant

Translational Development of a novel therapy for Malignant Mesothelioma

1 Jul 2022 to 31 Mar 2024

Awarded
£221,068
Total cost £315,811

There are an estimated 2.5 million people living with cancer in the UK, projected to increase up to 4 million by 2030\. Treatments and the outcomes for many cancers have improved, but not for rare, aggressive cancers such as Malignant Mesothelioma (MM). MM is an incurable cancer of the lining of the lung and chest (pleura) or abdominal cavity (peritoneum)...

2018 Collaborative R&D Lead participant

Formulation and testing of PLGA-DS as an anti-cancer therapy for FDA and EMA new drug application

1 Mar 2018 to 31 Mar 2020

Awarded
£147,082
Total cost £210,194

Due to the cost ($1.5 billion), time (15 years) and high failure rate (up to 95%) of novel drug development from new compounds, there is a global trend towards the repositioning of known drugs for the treatment of cancer. We have demonstrated that Disulfiram (DS), a long-established anti-alcoholism drug, possesses excellent anticancer activity with low to...

Product types

Collaborative R&D